Reid SM, et al. - In this study, researchers identified the efficacy of three anticholinergic drugs (benzhexol hydrochloride, glycopyrrolate, or scopolamine) in decreasing drooling in children with developmental disabilities (like cerebral palsy, intellectual disability, and autism spectrum disorder), the frequency and nature of side effects, and their effect on discontinuation of treatment. This investigation was carried out at The Royal Children’s Hospital and Murdoch Children’s Research Institute in Victoria, Australia. The study sample consisted of 110 children. For this investigation, benzhexol, glycopyrrolate, and scopolamine were prescribed 81, 62, and 17 times respectively, with respective response rates of 85%, 75%, and 65%. Glycopyrrolate produced the greatest improvement in drooling with some side effects vs benzhexol and scopolamine. Poor response was associated with poor head control and poor oromotor function. The side effects of medication were prevalent and often led to discontinuation of treatment. Behavioral problems caused benzhexol to be stopped more frequently in men than women.